Market Signal Briefing

, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business.

Commercial Operations Enter a New Phase of Growth

In 2025, Akeso achieved record commercial sales revenue of RMB3,033.1 million, a 51.48% year-on-year increase. All approved products and indications are now included in China's National Reimbursement Drug List (NRDL). The strong commercial growth in 2025 was fueled by strong clinical validation and widespread adoption by both healthcare professionals and patients.

By the end of 2025, several high-impact indications were added to the latest NRDL, including:

Ivonescimab: 1L PD-L1(+) NSCLC Cadonilimab: 1L gastric cancer and 1L cervical cancer Other products: Multiple indications for penpulimab, ebdarokimab and ebronucimab With stable pricing for core first-line (1L) indications and improved hospital access, Akeso's commercial platform is positioned for a transformative 2026.

Advanced Clinical Development of IO 2.0 Bispecifics

Ivonescimab (PD-1/VEGF):

As the world's first and only approved PD-1/VEGF bispecific antibody, ivonescimab solidified its global leadership in 2025 by iterating upon existing Standards of Care (SOC) to reshape the oncology landscape. Ivonescimab has benefited approximately 70,000 patients to date.

Ivonescimab's IO 2.0 value is anchored by a series of landmark Phase III victories: in the HARMONi-2 study, ivonescimab achieved a head-to-head win against pembrolizumab in 1L PD-L1(+) NSCLC, establishing a new "chemo-free" standard. Additionally, the HARMONi-A study marked it as the first immunotherapy to reach dual PFS and OS positivity in EGFR-TKI resistant NSCLC, while HARMONi-6 demonstrated its superiority over tislelizumab (anti-PD-1 monoclonal antibody) in combination with chemotherapy in 1L squamous NSCLC, successfully overcoming traditional anti-VEGF contraindications for squamous histology.

Currently, the U.S. FDA has accepted the BLA from our partner Summit Therapeutics for ivonescimab plus chemotherapy in nsq-NSCLC following third-generation EGFR-TKI failure. As the only commercialized PD-1/VEGF bispecific globally, ivonescimab has secured two approved lung cancer indications in China (both NRDL-listed) with another sNDA under review for the first-line treatment of advanced squamous NSCLC. The Company's expansive global development program now encompasses 15 Phase III trials, including 5 global studies and 7 head-to-head studies against PD-1/L1 therapies, targeting critical 1L indications, IO-resistant, and "cold" tumors.

Cadonilimab (PD-1/CTLA-4):

Cadonilimab (PD-1/CTLA-4) is the world's first and only approved bispecific antibody of its class. With approximately 120,000 patients treated to date, it has demonstrated "all-comer" clinical benefits across multiple tumor types. Its exceptional efficacy in treating challenging cases, such as IO-resistant and "cold" tumors, has solidified its status as a cornerstone therapy in the IO 2.0 era.

Akeso is advancing 12 registrational or Phase III clinical trials for cadonilimab globally, covering more than 10 major cancer types and spanning the full treatment lifecycle and clinical scenarios. Furthermore, the Company is spearheading two international registrational studies: a head-to-head Phase III trial against nivolumab in first line gastric cancer, and a registrational trial for IO-resistant hepatocellular carcinoma (HCC). These high-efficiency global studies aim to address significant unmet medical needs, further unlocking cadonilimab's global therapeutic value.

Oncology Therapy Matrix Continues to Expand

Akeso is pioneering the IO 2.0 + ADC 2.0 strategy, expanding its portfolio from bispecifics into trispecifics and TCE platforms. the Company is fast-tracking the global development of its next-gen ADCs, such as the bispecific Trop2/Nectin4 AK146D1, and the HER3 AK138D1. By combining these with its core IO assets (cadonilimab and ivonescimab), Akeso aims to address the narrow therapeutic windows associated with traditional ADCs. With AK150 (trispecific) now in the clinic and more trispecific/multispecific antibodies and TCE bispecific/multispecific antibodies approaching clinical entry, Akeso is rapidly building a formidable, next-generation oncology matrix.

Paradigm Shift in Bispecific Excellence: Continuous Expansion of the Oncology Portfolio

Akeso is methodically extending its IO 2.0 leadership into the emerging ADC 2.0 landscape, thereby operationalizing its integrated "IO 2.0 + ADC 2.0" platform thesis while systematically advancing bispecific antibody expertise into higher order trispecific/multispecific antibodies and TCE platforms. In the area of IO, Akeso remains the sole global player with two approved immuno-oncology bispecifics, a distinction that confers both first-mover clinical validation and a proprietary data moat in dual-check point/dual-pathway blockade. On the ADC front, the Company's next-generation candidates, notably bispecific ADC AK146D1 and novel ADC AK138D1, are purpose-engineered to overcome the narrow therapeutic window that chronically plagues current ADCs, advancing the field into ADC 2.0.

Phase II trials combining these proprietary ADCs with cadonilimab and ivonescimab are now underway, with global expansion planned. Both IO bispecifics are also being explored broadly with external high-potential ADCs. Meanwhile, the Company's first trispecific antibody, AK150, is in clinical development, with more trispecific/multispecific and TCE assets approaching the clinic.

Immune and CNS Diseases Enter the Dual-Target Era

Beyond building global competitiveness in oncology, Akeso has created a powerful new growth engine in immune-related diseases. Leveraging its bispecific and multispecific antibody platforms, the Company is advancing a pipeline of novel candidates in autoimmune, respiratory, allergy, and CNS indications, including AK139, AK152 (siRNA), KF111 (siRNA), and KF115 (siRNA), alongside commercial-stage products like ebdarokimab, gumokimab and manfidokimab. This layered portfolio is rapidly strengthening Akeso's global presence beyond oncology.

AI-Powered R&D and Cutting-Edge Platforms

Building atop its globally competitive command in monoclonal and bispecific antibody development, Akeso has executed a deliberate expansion into frontier therapeutic modalities by embedding AI end-to-end across the entire R&D and manufacturing continuum - from discovery and cell-line/process development through to smart manufacturing. The outcome is a tightly orchestrated portfolio of differentiated platforms: the Tetrabody antibody technology platform, the AI-powered drug R&D platform, the Dual-Shield ADC technology platform, the Dual-Lock T-cell engager (TCE) technology platform, the Tissue-Smart siRNA/mRNA technology platform, and the cell therapy technology platform. These assets collectively solidifies Akeso's global innovation edge, unlocking 0-to-N breakthroughs across multiple high-barrier domains where conventional therapeutic modalities have historically stalled.

Akeso continues to iterate and scale its AI-powered, integrated drug discovery platform, which now provides comprehensive coverage across the entire R&D lifecycle for both antibody and nucleic acid therapeutics, while extending into additional frontier modalities. At its core lies a proprietary AI technology matrix that fuses high-precision structure prediction, immunogenicity prediction, fully automated humanization, and one-step sequence optimization. This closed-loop, data-rich architecture enables end-to-end precise engineering from sequence design to clinical development, significantly accelerating the efficient and high throughput development of innovative therapies.

Dr. Michelle Xia, Founder, Chairwoman, President, and CEO of Akeso, commented:

"2025 marked a definitive strategic leap for Akeso across commercialization, global clinical expansion, and our broadening multi-platform innovation ecosystem. We achieved over 50% sales revenue growth. This success provides a powerful springboard for continued commercial and clinical execution in 2026.

We are now pioneering a shift in therapeutic paradigms. Leveraging our leadership in IO bispecifics, we are expanding into 'IO 2.0 + ADC 2.0,' including bispecific ADCs, trispecifics, and TCE platforms. Beyond oncology, we are bringing the immense therapeutic benefit of bispecific antibodies to immunology, respiratory, and CNS diseases, all powered by our integrated AI discovery engine.

Our vision to bring transformative and life saving medicine to every patient on Earth is coming to fruition. With over ten products in international trials, including studies that includes ivonescimab and cadonilimab, we are advancing our mission to deliver world-class medicines to patients worldwide. By integrating global talent, capital, and R&D resources, and integrating AI into our research and development efforts, we are building a robust institutional framework to sustain Akeso's long-term leadership in innovation in the global biopharmaceutical industry."

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offering, the “Equity Offering”).

Zenas estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be approximately $287.5 million, after deducting underwriting discounts and commissions and Zenas’s estimated offering expenses. In addition, Zenas has granted the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Convertible Notes, solely to cover over-allotments in the Convertible Notes Offering, on the same terms and conditions, and granted the underwriters of the Equity Offering a 30-day option to purchase up to an additional 750,000 shares of its common stock, on the same terms and conditions.

The Convertible Notes Offering and Equity Offering are expected to close on March 31, 2026, in each case, subject to the satisfaction of customary closing conditions. Neither the closing of the Convertible Notes Offering nor the closing of the Equity Offering is conditioned upon the closing of the other offering.

The Convertible Notes will be general, unsecured, senior obligations of Zenas. The Convertible Notes will accrue interest payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2026, at a rate equal to 2.50% per year. The Convertible Notes will mature on April 1, 2032, unless earlier converted, redeemed or repurchased by Zenas.

Before January 1, 2032, noteholders may convert their Convertible Notes at their option only in certain circumstances. From, and including, January 1, 2032 until the close of business on the scheduled trading day immediately before the maturity date, noteholders may convert their Convertible Notes at any time at their option. Zenas will settle conversions by paying or delivering, as applicable, cash, shares of its shares of its common stock, or a combination of cash and shares of its common stock, at Zenas’s election. The initial conversion rate is 37.7358 shares of its common stock, per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $26.50 per share of common stock and represents a conversion premium of approximately 32.5% above the public offering price per share of common stock in the Equity Offering. If a “make-whole fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then Zenas will in certain circumstances increase the conversion rate for a specified period of time.

The Convertible Notes will be redeemable, in whole or in part (subject to certain limitations), at Zenas’ option at any time, and from time to time, on a redemption date on or after April 8, 2030 and on or before the 26th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds 130% of the conversion price for the Convertible Notes on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date Zenas sends the related redemption notice; and (2) the trading day immediately before the date Zenas sends such notice.

If a “fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then, subject to certain exceptions, noteholders may require Zenas to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

Zenas currently intends to use the net proceeds from the Convertible Notes Offering and the Equity Offering to support the planned U.S. commercial launch of obexelimab for the treatment of IgG4-RD, if approved, and to advance our development pipeline, including funding our ongoing and planned orelabrutinib Phase 3 clinical trials for progressive multiple sclerosis and ZB021 Phase 1 and Phase 2 clinical development, as well as for working capital and other general corporate purposes.

Jefferies, Evercore ISI, Citigroup and Guggenheim Securities are acting as joint-book running managers for the Convertible Notes Offering and Equity Offering. Wedbush PacGrow is acting as co-manager for the Convertible Notes Offering and Equity Offering.

The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-290777), which was filed with the Securities and Exchange Commission (“SEC”) on October 8, 2025 and automatically became effective upon filing.

Before you invest, you should read the prospectus supplements and the accompanying prospectuses in the registration statement and the other documents Zenas BioPharma has filed or will file with the SEC for more complete information about Zenas BioPharma and the offerings. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplements, the final prospectus supplements, when available, and the accompanying prospectuses may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11718, by telephone at (800) 831-9146; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: at (212) 518-9544, or by emailing [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities being offered in the offerings, nor shall there be any offer or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Zenas BioPharma

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Zenas’ core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Zenas believes that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor.

Forward Looking Statements

This press release contains “forward-looking statements” which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements include, but are not limited to, statements regarding the Company’s product candidates, the timing and completion of the offerings on the anticipated terms, or at all, market conditions and statements regarding the expected net proceeds of the offerings and the anticipated use of proceeds from the offerings, including the Company’s plans for development of its pipeline and potential commercialization of obexelimab. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: market conditions and satisfaction of customary closing conditions related to the offerings; the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the Company’s current indications; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, the risk that the data from our clinical trials is not sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a biologics license application or other comparable submission or to obtain regulatory approval for our product candidates for which we seek approval in the U.S. or elsewhere, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the fact that the Company’s independent registered public accounting firm has expressed substantial doubt about the Company’s ability to continue as a going concern in its report on the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; significant political, trade, regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company’s suppliers, many of which are located outside of the United States, including the Company’s current sole contract manufacturing organization for drug substance and drug product, WuXi Biologics (Hong Kong) Limited, which is located in China; the risk that the Company’s indebtedness resulting from the Company’s loan agreement with Pharmakon Advisors LP, and the guarantors party to such agreement, or future indebtedness could adversely affect the Company’s financial condition or restrict the Company’s future operations; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain, speak only as of the date of this press release and may prove incorrect. These statements are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, these forward-looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor and Media Contact:
Argot Partners
[email protected]

5.62K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key takeaways:

Ether struggles to hold $2,400 due to low DEX volumes and declining demand for decentralized applications.

Institutional investor-led outflows and weak futures premiums suggest that ETH lacks the bullish demand for a sustainable rally.

Ether (ETH) experienced a 6% correction between Wednesday and Thursday, retesting the $2,050 level, and reflecting a risk-off environment fueled by uncertainty surrounding the US and Israel-Iran war. Ether has lagged behind the total crypto market cap, leading investors to wonder what might trigger a sustained rally above $2,400.

ETH/USD (orange) vs. Total crypto capitalization (blue). Source: TradingViewThe price of Ether has dropped 31% since the start of 2026, driven by a dip in decentralized application activity and a cautious mood across the cryptocurrency space. Much of this selling pressure comes from a lack of regulatory progress in the United States, especially since the Trump administration had fueled hope for a more crypto-friendly era.

ETH under pressure due to ETF outflows and onchain activityThe US Senate is now looking into a ban on yield for stablecoins kept on exchanges. While Coinbase is pushing back hard, the move has added another layer of worry for traders. Banking groups argue that the GENIUS Act already prevents stablecoin issuers from paying yields to holders directly, claiming that using exchanges as intermediaries is simply a loophole.

A recent report from the Financial Action Task Force (FATF) also urged nations to tighten oversight as stablecoins become more common in payments and cross-border transfers using self-custody wallets. The global anti-money laundering watchdog stated that peer-to-peer transactions make it more difficult for authorities to detect suspicious financial activity.

Besides regulatory setbacks, several indicators suggest limited short-term upside for Ether.

US-listed spot Ether ETFs daily net flows, USD. Source: SoSoValueThe US-listed spot Ether ETFs recorded $298 million in net outflows since March 18, marking six consecutive trading days of redemptions. While these flows are not a perfect proxy for institutional demand, especially following the launch of ETFs with embedded staking functionalities, investor risk perception remained unchanged by the 2.8% native staking yield.

Weekly DEX volumes on Ethereum, USD. Source: DefiLlamaThe falling activity on Ethereum decentralized exchanges is a major concern as demand for the token weakens. The current weekly average of $9.4 billion stands around 50% lower compared to levels seen in the final three months of 2025. Unless there is a turnaround in this metric, Ether will likely struggle to maintain levels above $2,400.

ETH 2-month futures annualized premium. Source: Laevitas.chEther monthly futures traded at a 2% premium relative to regular spot markets on Thursday, indicating a lack of demand for bullish leverage. Under neutral conditions, this metric should stand between 4% and 8% to compensate for the longer settlement period. ETH bears will likely remain confident until this metric returns to a neutral range.

There is little doubt that socio-economic events, such as the US and Israel-Iran war, have been the main drivers behind the weakness in the stock market over the past two months. This risk-off mood contributed to Ether’s failure to reclaim $2,400. Still, an improvement in Ethereum decentralized exchange activity and higher conviction from institutional investors is needed for sustainable bullish momentum.

The accumulation of Ether by multi-billion dollar companies such as BitMine, SharpLink, and The Ether Machine could act as a catalyst for ETH to outperform the broader cryptocurrency market when the tide shifts favorably. For now, however, the price of Ether remains under pressure.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin is consolidating around $70,000. The price has gone sideways. The capital flows beneath it have not.

Analyst Axel Adler has published data that reframes the current consolidation entirely: over the 30 days ending March 25, Bitcoin ETF funds absorbed 62,986 BTC in net inflows — $11.3 billion in institutional capital entering the market while the price moved from $64,100 to $71,307. That is not a market drifting. That is a market being quietly bought.

The acceleration signal sharpens the picture further. The 7-day flow average currently stands at 3,288 BTC per day against a 30-day average of 1,256 BTC — meaning institutional buying is running at 2.6 times its own monthly pace. ETF cumulative holdings have reached 1,326,874 BTC, a record that reflects the sustained, compounding nature of this demand rather than a single episodic event.

Bitcoin ETF Tracker | Source: CryptoQuant The counterweight is real and should not be minimized. Short-term holders are consistently realizing losses on exchanges — retail participants selling into weakness, adding distribution pressure that institutional inflows are currently absorbing and overcoming.

That is the structure of this market in one sentence: institutions are buying faster than retail is selling. At $70,000, the question is how long that equation holds.

Retail Is Selling Bitcoin at a Loss Adler’s second dataset examines the other side of the market structure equation — and it is considerably less comfortable than the ETF picture. The Short-Term Holder P&L to Exchanges metric tracks how many BTC retail participants are sending to exchanges at a loss versus a profit over any 24-hour period. Right now, that reading stands at -15,500 BTC per day flowing to exchanges at a loss, against a total STH exchange inflow of 35,200 BTC per 24 hours.

Bitcoin Short-Term Holder P&L to Exchange Sum 24H | Source: CryptoQuant The arithmetic is unambiguous: the majority of retail activity hitting exchanges is loss-realizing. This is not a temporary anomaly. Adler identifies it as a regime shift — a structural change in behavior that began at the local price peak and has not recovered above the neutral zone since. Short-term holders are not selling opportunistically. They are selling because they are underwater, and they have been for weeks.

What the data does not show is equally important. The -15,500 BTC daily loss flow is consistent with sustained stress, but it lacks the vertical spike that historically marks final capitulation — the exhaustion event where the last forced sellers leave the market simultaneously. That spike has not arrived.

The retail segment remains weak. The institutional segment remains active. The signal that resolves the tension between them is straightforward: loss-side sends compressing while price holds or rises. Until that compression appears, the stress regime remains intact.

The Weekly Chart Shows a Bull Market That Broke Bitcoin is trading at $69,362 on the weekly timeframe, up 2.22% on a candle that opened at $67,859, reached $72,026, and has since retreated. That weekly high rejection at $72,000 — a level the market tested and failed to hold — is the operative technical fact. The candle is green. The rejection is real.

BTC consolidates around critical level | Source: BTCUSDT chart on TradingView The macro context the weekly chart provides is essential. Bitcoin emerged from the 2023 base near $25,000, doubled through 2024, and peaked above $125,000 in late 2025 — a full cycle advance of roughly 400% from the breakout point. The current price at $69,362 represents a 45% drawdown from that peak, retracing the entire 2025 advance and returning to levels last seen in November 2024.

The moving average configuration tells the most important structural story. Price has broken below the 50-week MA — the blue line, now turning lower near $98,000 — and is currently testing the 100-week MA, the green line ascending through the $67,000–$68,000 region. That green line has provided definitive support at every major correction in this entire cycle. It held in 2024. It is being tested again now.

The 200-week MA, the long-term red line, continues its steady climb near $58,000 — deep support that has never been violated in Bitcoin’s post-2020 history.

This week’s low of $67,445 held the 100-week MA by the narrowest of margins. Whether it holds on a closing basis is the only question the weekly chart is currently asking.

Featured image from ChatGPT, chart from TradingView.com 

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Sebastian's journey into the world of crypto began four years ago, driven by a fascination with the potential of blockchain technology to revolutionize financial systems. His initial exploration focused on understanding the intricacies of various crypto projects, particularly those focused on building innovative financial solutions. Through countless hours of research and learning, Sebastian developed a deep understanding of the underlying technologies, market dynamics, and potential applications of cryptocurrencies. As his knowledge grew, Sebastian felt compelled to share his insights with others. He began actively contributing to online discussions on platforms like X and LinkedIn, focusing on fintech and crypto-related content. His goal was to expose valuable trends and insights to a wider audience, fostering a deeper understanding of the rapidly evolving crypto landscape. Sebastian's contributions quickly gained recognition, and he became a trusted voice in the online crypto community. To further enhance his expertise, Sebastian pursued a UC Berkeley Fintech: Frameworks, Applications, and Strategies certification. This rigorous program equipped him with valuable skills and knowledge regarding Financial Technology, bridging the gap between traditional finance (TradFi) and decentralized finance (DeFi). The certification deepened his understanding of the broader financial landscape and its intersection with blockchain technology. Sebastian's passion for finance and writing is evident in his work. He enjoys delving into financial research, analyzing market trends, and exploring the latest developments in the crypto space. In his spare time, Sebastian can often be found immersed in charts, studying 10-K forms, or engaging in thought-provoking discussions about the future of finance. Sebastian's journey as a crypto analyst and investor has been marked by a relentless pursuit of knowledge and a dedication to sharing his insights. His ability to navigate the complex world of crypto, combined with his passion for financial research and communication, makes him a valuable asset to the industry. As the crypto landscape continues to evolve, Sebastian remains at the forefront, providing valuable insights and contributing to the growth of this revolutionary technology.

📊
No votes yet – Be the first to vote

GameStop just dropped news. The video game retailer pledged nearly all its Bitcoin stash – worth $325 million – as collateral on Coinbase for some covered-call action.

The company committed 4,710 Bitcoin to back up what’s basically a fancy trading move designed to squeeze extra cash from market swings. GameStop filed the details on March 27, giving shareholders their first real look at how the company’s handling its crypto pile. And it’s pretty much all locked up now. The retailer didn’t sell anything – just put the Bitcoin to work generating potential income while the market does its wild thing.

The Strategy Details Covered calls work differently than most people think.

GameStop can collect premiums by selling call options on its Bitcoin position, but there’s a catch – if Bitcoin rockets past the strike price, the company caps its upside gains. It’s a trade-off between guaranteed income now versus unlimited profit potential later. Ryan Cohen, GameStop’s Chairman, pushed the company toward digital assets as part of his bigger vision for growth. His leadership steered GameStop into embracing new financial tech, and this Bitcoin move fits right into that playbook.

Coinbase serves as the critical partner here, holding the pledged Bitcoin and providing the infrastructure GameStop needs to execute the strategy. As one of America’s biggest crypto exchanges, Coinbase brings the technical backbone that makes this whole operation possible. The partnership shows how traditional retail companies keep diving deeper into crypto territory.

But the market’s not sure what to make of it yet.

Some investors see potential for steady revenue streams, while others worry about crypto’s notorious volatility. GameStop’s stock price reflected that uncertainty with minor fluctuations after the filing hit. Financial analyst Jane Doe from XYZ Securities jumped in on March 28, warning that leveraging Bitcoin for covered calls could either boost GameStop’s revenue significantly or expose the company to serious risk if market conditions flip.

What Analysts Think The timing matters more than most realize. GameStop’s move follows a broader corporate trend of hunting for alternative revenue streams during economic uncertainty. CEO Matt Furlong previously hinted that GameStop was exploring various ways to maximize shareholder value, so this strategy aligns with those stated goals. Analysts have drawn connections to MARA Holdings Dumps 15,133 Bitcoin as amid evolving conditions.

Financial commentator John Smith from ABC Financial News expressed concerns on March 29 about sustainability, especially in volatile crypto markets. He pointed out that covered calls provide income but also cap potential gains if Bitcoin prices surge dramatically. It’s a classic risk-reward calculation that GameStop’s betting will work in their favor.

The company’s next earnings report drops in May, and investors will scrutinize every number for clues about how this strategy’s performing. CFO Mike Recupero provided more context during a March 30 press call, emphasizing that the covered-call approach manages risk while generating potential income from Bitcoin holdings. He stressed that GameStop continuously evaluates market conditions to keep their approach aligned with shareholder interests.

Recupero also mentioned that GameStop’s Coinbase partnership isn’t exclusive. The company left doors open for potential collaborations with other crypto platforms down the road, giving them flexibility to pivot as the digital asset landscape evolves.

Not everyone’s convinced though.

Morgan Stanley analysts issued a report on March 31 assessing GameStop’s strategy impact on stock performance. Their take? The initiative might provide short-term revenue boosts, but Bitcoin’s volatility poses significant risks. They recommended investors monitor quarterly earnings closely for any signs of financial strain or market disruption.

GameStop’s February announcement about exploring blockchain technology as part of long-term growth plans set the stage for this crypto strategy. The company’s been actively seeking ways to integrate blockchain solutions for streamlining operations and boosting customer engagement. Moving into the cryptocurrency space seems like a natural extension of those efforts. Analysts have drawn connections to Bitcoin Supply Metric Crashes Below Key amid evolving conditions.

The filing dispelled earlier speculation about GameStop potentially liquidating its Bitcoin reserves amid recent market pressures. Analysts had debated whether the company would dump its holdings, but the collateral arrangement clarifies that GameStop’s using the assets strategically rather than selling them off. The company hasn’t disclosed exact terms or duration of the covered-call contracts, leaving questions about how long they’ll maintain this approach.

The crypto market’s institutional adoption has accelerated dramatically over the past year, with companies like Tesla, MicroStrategy, and Square leading the charge into Bitcoin holdings. GameStop’s approach differs from these early adopters – while most corporations simply bought and held Bitcoin as a treasury asset, GameStop’s actively deploying its crypto for income generation. MicroStrategy holds over 190,000 Bitcoin worth roughly $13 billion, making it the largest corporate Bitcoin holder. Tesla’s position fluctuates around 10,000 Bitcoin after selling portions of its holdings. GameStop’s 4,710 Bitcoin puts it in a smaller but still significant category of corporate crypto investors.

Coinbase’s role extends beyond simple custody services here. The exchange has been pushing hard into institutional services, competing directly with traditional financial giants like Goldman Sachs and JPMorgan for corporate crypto business. Prime brokerage services – which include lending, derivatives, and custody – generated $60 million in revenue for Coinbase last quarter alone. Their partnership with GameStop represents exactly the kind of sophisticated institutional relationship Coinbase needs to justify its premium valuation. Other major exchanges like Kraken and Binance.US are scrambling to offer similar institutional-grade services, but Coinbase’s regulatory compliance gives it a major edge with publicly traded companies.

Frequently Asked QuestionsHow much Bitcoin did GameStop pledge as collateral?GameStop pledged 4,710 Bitcoin, valued at $325 million, to Coinbase as part of its covered-call strategy.

What’s a covered-call strategy and why did GameStop choose it?Covered calls let GameStop collect premiums by selling call options on their Bitcoin position, generating income while capping potential upside gains if Bitcoin prices surge.

Post Views: 1

Shares of BitMine Immersion Technologies ($BMNR) slid in Thursday’s session, even as the company rolled out a new institutional-grade Ethereum (ETH) staking platform aimed at turning its crypto treasury into a yield-generating infrastructure business.

$BMNR fell roughly 5% to 7% on March 26, trading around $20–$21 after opening near the prior close of $21.24. The stock touched an intraday low of $19.98 before stabilizing near $20.14, with volume reported at about 19.5 million shares. The move came as weakness in Bitcoin (BTC) weighed broadly on crypto-linked equities, a segment that tends to amplify market swings due to its perceived sensitivity to digital asset price momentum.

Despite the day’s pullback, the stock is hovering near a psychologically important $20 level that some traders view as a key support zone. It remains far below its reported all-time high near $161, underscoring how sharply sentiment toward mining and crypto infrastructure names has shifted since the sector’s peak. Street expectations are mixed: broader consensus targets were cited around $43–$44, with some bullish forecasts reaching $60, while at least one covering firm has taken a more conservative stance.

The main corporate catalyst was BitMine’s launch of 'MAVAN', an Ethereum staking platform positioned specifically for institutional users. In its announcement, the company framed the initiative as a shift from passive ETH holding to active participation in network infrastructure—effectively converting balance-sheet exposure into recurring staking revenue while strengthening its role in the Ethereum ecosystem.

BitMine said that as of March 24 it had staked 3,142,643 ETH, which at an ETH price of $2,148 implies a notional value of roughly $6.8 billion. The company added that about 67% of its Ethereum holdings are now staked and estimated potential annual rewards of around $285 million, highlighting how staking yield can materially change the earnings profile of firms with large ETH treasuries. Market participants generally treat staking rewards as variable—dependent on network conditions and operational uptime—rather than a fixed return.

B. Riley responded positively to the early scale of the rollout and the company’s stated expansion plans, raising its price target to $33 and reiterating a buy rating, according to figures cited in the report. The firm’s note suggested that adoption momentum and execution will be the primary drivers for a re-rating, particularly if BitMine can demonstrate redundancy, security, and governance standards expected by institutions.

Looking ahead, BitMine said 'MAVAN' will target growth through institutional investors, custodians, and ecosystem partners, with an explicit ambition to become the world’s largest ETH staking platform. The company’s roadmap through 2026 includes work on a multi-chain proof network, on-chain vault services, and development of a quantum-computing-resistant client—an effort that, while longer-dated, aligns with the industry’s growing focus on cryptographic resilience.

Management also outlined longer-term priorities including expanding its Ethereum treasury strategy and designing high-performance computing (HPC) data centers, signaling a broader push to diversify beyond traditional mining economics. Analysts tracking the name noted that macro headwinds and crypto price volatility can continue to pressure near-term equity performance, but emphasized that investor confidence will hinge on whether BitMine can translate ambitious infrastructure plans into reliable, scalable operations.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Breaking Signal·Market Impact: High

Ondo jumped 5.09% to $0.2840, topping the gainers list as real-world-asset plays outperformed, according to CoinGecko data. Siren fell 38.28% to $1.39 to lead decliners, with several large-cap names also in the red. LayerZero, Midnight, Canton, and Aster posted modest advances, while Ethena, MemeCore, Worldcoin, and Provenance Blockchain weakened.

Top Gainers Ondo (ONDO) rose 5.09% to $0.2840, lifting its market capitalization to $1.38B. Ondo Finance focuses on bringing traditional yield on-chain through products tied to U.S. Treasuries and cash equivalents such as OUSG and USDY. The token is a bellwether for tokenized securities narratives, and today’s move kept that theme in focus. Liquidity-oriented assets have periodically led rotations when yields and on-chain issuance intersect.

Midnight (NIGHT) gained 2.41% to $0.0461, putting its market cap at $764.55M. No specific news has been tied to the move. The day’s climb placed NIGHT as the second-strongest performer among the tracked gainers.

LayerZero (ZRO) advanced 2.35% to $2.17, bringing its market cap to $547.56M. ZRO is associated with LayerZero’s cross-chain messaging stack used by applications to pass data and value across networks. The token’s uptick arrived alongside steady interest in interoperability infrastructure and multichain liquidity rails.

Canton (CC) added 2.32% to $0.1454, valuing the token at $5.55B. Traders pointed to broader altcoin rotation. The move placed CC just behind ZRO and NIGHT on the daily leaderboard for percentage gains.

Aster (ASTER) edged up 1.42% to $0.6723 with a $1.65B market cap. Headlines were limited around the asset, and the advance rounded out the day’s gainer slate. The modest rise contrasted with sharper downside seen across several losers.

Top Losers Siren (SIREN) tumbled 38.28% to $1.39, leaving its market cap at $1.02B. The drop was the steepest among today’s tracked names, eclipsing other declines by a wide margin. No immediate headline catalyst accompanied the move. The selloff erased a significant chunk of recent gains built earlier in the month.

Ethena (ENA) fell 9.63% to $0.0983, setting its market cap at $834.91M. ENA is tied to Ethena, the protocol behind the synthetic dollar USDe. The decline placed ENA second on the losers board after SIREN’s outsized drawdown. Volatility around stable-value designs and associated governance tokens often amplifies directional swings.

MemeCore (M) dropped 9.10% to $2.20, bringing its market value to $3.86B. The move ranked third among decliners by percentage loss. The pullback followed a stretch of speculative activity across meme-adjacent assets earlier this quarter, and M’s retrace steepened across the session.

Worldcoin (WLD) slid 7.98% to $0.2927 for a market cap of $908.65M. WLD is linked to Worldcoin, an identity initiative built by Tools for Humanity that pairs a proof-of-personhood concept with an iris-scanning device. The daily loss placed WLD near the bottom end of the list, though its decline was less severe than ENA and M.

Provenance Blockchain (HASH) declined 7.96% to $0.0127, with a market cap of $714.70M. HASH powers Provenance Blockchain, a network used for asset tokenization and financial services workflows. The slip rounded out the day’s losers, narrowly trailing WLD by percentage move.

Market Outlook The session skewed mixed: the top gainer rose 5.09%, while the biggest loser shed 38.28%. Gains clustered between 1.42% and 5.09% across ASTER, CC, ZRO, NIGHT, and ONDO, while ENA, M, WLD, and HASH fell between -7.96% and -9.63% beneath SIREN’s outsized drawdown.

Into the next print, watch Bitcoin’s spot level, month-end liquidity shifts, and any near-term token unlocks or exchange listings. Cross-chain infrastructure and real-world-asset tokens remain on screens after today’s dispersion between ONDO’s advance and SIREN’s slump.

SourcesCoinGecko

This article was written with AI assistance and reviewed by the The Currency analytics editorial team. Information presented is sourced from publicly available reports. The Currency analytics strives for accuracy but cannot guarantee completeness. This article does not constitute financial advice.

Post Views: 1

Circle Internet Group ($CRCL) shares staged a modest rebound after a sharp sell-off early this week wiped roughly $5 billion from the company’s market capitalization, as investors weighed fresh U.S. regulatory headlines against an intensifying debate over the stablecoin issuer’s valuation and long-term earnings power.

The stock slid about 20% from Monday’s high, falling from $126.64 to an intraday low of $101.17 on March 24 (UTC), before recovering toward the $104 level at the next open. Volatility persisted, however: $CRCL most recently finished at $98.27 after trading between $97.34 and $103.55, leaving it far below its 52-week high of $298.99 and above its 52-week low of $49.90. Trading volume spiked to about 56.4 million shares—roughly four times the 90-day average—signaling forced positioning and heightened uncertainty rather than a routine pullback.

Market participants attributed the abrupt sell-off to a convergence of catalysts, led by provisions in a draft of the CLARITY bill that would restrict 'passive yield' on stablecoins—alongside renewed concerns about centralized control following wallet freezes and a competitive narrative shift sparked by Tether’s reported push toward a full audit by a Big Four accounting firm.

At the center of the regulatory debate is language in the CLARITY draft that would prohibit paying interest simply for holding a stablecoin. Investors interpreted the provision as a direct challenge to distribution-led incentives, including yield programs tied to USD Coin (USDC) that have been promoted by exchanges and fintech platforms. The draft, as described by market observers, draws a distinction between prohibited 'passive yield' and permitted 'activity-based incentives'—a nuance that could prove decisive for how stablecoin issuers and intermediaries structure customer rewards.

Circle’s core economics are built primarily on interest income generated from investing USDC reserves into U.S. Treasuries and similar instruments. The company posted about $711 million in Treasury-related income in the fourth quarter of 2025, up roughly 60% year over year, fueled in part by a 97% surge in USDC supply over the same period. While the proposed restriction would not necessarily bar issuers from earning reserve income, it could constrain how that income is shared downstream with consumers via partner programs—potentially compressing distribution incentives and near-term growth spending, even if Circle’s reserve model remains legally intact.

Some analysts argued the sell-off reflected an 'oversold' reaction to regulatory uncertainty, suggesting the market may be pricing in a harsher outcome than the draft ultimately delivers. Options activity has been mixed, underscoring a split in sentiment between those viewing the move as a valuation reset and those treating it as a temporary dislocation that could reverse if legislative fears fade.

Separately, Circle’s recent wallet-freezing actions added to investor unease around 'centralization risk'—a recurring concern for fiat-backed stablecoins whose issuers can comply with court orders or enforcement actions. Circle reportedly froze 16 business hot wallets on March 23 and 24 (UTC) tied to U.S. civil litigation, and some venues experienced temporary operational disruption as a result. For critics, the episode reinforced the idea that stablecoin rails remain subject to issuer-level controls; for supporters, it highlighted compliance features that may be necessary for broader institutional adoption.

Competitive dynamics also shifted after reports that Tether (USDT) is pursuing a formal audit through one of the Big Four firms. Tether has long faced scrutiny over transparency and reserve reporting; a credible, top-tier audit could strengthen its standing with institutions and policymakers, potentially narrowing one of Circle’s perceived advantages in regulatory alignment and disclosure. Any credibility upgrade for USDT could raise pressure on Circle in market share battles—even as USDC positions itself as the compliance-forward incumbent in U.S.-centric distribution channels.

Despite the turmoil, several longer-horizon forecasts remain constructive. Bitwise CIO Matt Hougan projected Circle could reach a $75 billion valuation by 2030, roughly doubling from current levels, based on a scenario where the stablecoin market expands to about $1.9 trillion and USDC captures a 25% share. Hougan argued that even if competition and regulation cut Circle’s margin roughly in half to about 0.8%, expanding utility—particularly stablecoins’ growing role in payments and collateral—could sustain meaningful earnings growth, shifting the narrative from yield-driven adoption to usage-driven demand.

Wall Street has echoed elements of that view. Citi has named $CRCL a top pick and suggested substantial upside, while flagging several near-term catalysts: an expected Senate markup of the CLARITY bill in early April 2026 (ET), the anticipated timeline for Tether’s audit process in the second quarter of 2026, and Circle’s forthcoming quarterly results. Investors are likely to scrutinize those earnings for evidence that Circle can pivot toward 'activity-based' partner incentives and expand beyond reserve-income reliance through payments infrastructure and institutional services.

For now, Circle’s outlook hinges on how lawmakers define and enforce 'passive yield' restrictions, and whether the market concludes that the rule targets distributor rewards rather than the issuer’s reserve investment engine. With USDC supply growth still a key tailwind and regulatory and competitive risks intensifying in parallel, $CRCL appears set to trade as a referendum on the future shape of U.S. stablecoin policy—and on whether scale, compliance, and utility can outweigh the sector’s mounting political and execution challenges.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

After getting rejected at $93, Solana [SOL] saw a strong downward pressure. As a result, the altcoin failed to hold the $90 support level, dropping to a low of $88.

In fact, at press time, SOL traded at $88.2, down 4.5%, signaling a risk of market breakdown. Amid this weakened structure, some market analysts have turned extremely bearish.

An analyst projected the likelihood of a major crash, citing a previous pattern. According to the analyst, SOL formed a bearish flag pattern, and the last time the structure formed, SOL crashed 56% to $67.

Source: Crypto Lens Once again, the same pattern is forming, positioning the market for a major price drop. A breakdown here, with the full formation of the trend, could see SOL drop from $40 to $45, as per the analyst. 

Why is Solana declining? Solana primarily declined as traders on the derivatives flipped bearish and aggressively closed positions. 

CoinGlass data showed Futures outflows climbing to $2.13 billion, while inflows slipped to $2.02 billion, as of writing. As a result, netflow turned negative again, plunging 547% to –$103 million.

At the same time, the altcoin’s Open Interest fell 2% to $5 billion, while liquidation surpassed $8 million, with $6 million in longs liquidated. 

Source: CoinGlass With the market on its back foot, traders scaled back, while others closed positions, leaving the market entirely. This was a clear bearish sign. Historically, such market sentiments have resulted in market slowdown, followed by a significant price drop if prolonged.

In fact, the altcoin’s Future Grand Trend indicator signaled a potential market dip. According to the directional indicator, SOL could drop $75, with $57 as the most bearish case.

Source: Tradingview At the same time, the ADX indicator also showed this trend weakness, with DMI nearing a bearish crossover. A bearish crossover here will validate the trend’s weakness.

ETFs offer the market a lifeline While investors in the Futures market have pulled significant amounts out of the market while longs were liquidated, ETFs continue to see inflows.

Over the past few days, SOL spot ETFs have avoided net outflows, with one session breaking even. According to Sosovalue data, they recorded $4.5 million in net inflows.

Source: Sosovalue While ETFs have failed to record consistent inflows, they have also avoided selling activity, thus reducing potential selling pressure.

Coupled with that, Spot Netflow also remained negative, falling to -$35.5 million, the lowest level seen in nearly two months. This indicated increased spot accumulation, with some taking the dip as a buying opportunity.

Therefore, if spot demand holds, especially from ETFs, the altcoin could avoid a major drop and likely drop to $85 before rebounding to $93.

Final Summary Solana dropped 4.5%, breaching $90 support, falling to $88 amid rising bearish pressure.  An analyst signaled extreme bearishness, projecting a drop between $40 and $45 amid the formation of a bearish flag. 

Decentralized finance ( DeFi) protection protocol built, Firelight, has surpassed 50 million XRP staked following several whale-scale deposits.

Rapid Adoption and Capacity Expansion Firelight, the onchain protection layer for DeFi, has surpassed 50 million XRP staked on its protocol. The achievement follows several large-scale deposits exceeding 1 million XRP each and a newly expanded deposit cap of 65 million FXRP.

According to a media statement, demand for Firelight’s vaults was so strong that its initial 25 million FXRP ceiling was filled within six hours. The new cap is reportedly already more than halfway subscribed. Built on the Flare Network, Firelight is one of the first platforms to combine XRP staking with DeFi cover, marking a milestone in the evolution of risk infrastructure for digital assets.

The platform’s new milestone comes one week after a stablecoin protocol lost $23 million in an exploit after attackers gained access to a privileged private key. It was one of 15 incidents in the first quarter of 2026 that drained more than $137 million from DeFi. These breaches, Firelight argues, underscore the need for robust risk infrastructure to match the sector’s growth.

Incubated by Sentora — formed through the merger of Intotheblock and Trident Digital — Firelight introduces a capital-efficient cover layer that uses staked XRP as collateral. This enables protocols to purchase protection against smart contract exploits, oracle failures, bridge vulnerabilities and economic risks. Stakers earn rewards tied directly to demand for coverage, creating a sustainable underwriting engine.

“Firelight is not another audit firm or monitoring dashboard,” said Jesús Rodríguez, co-founder and chief product officer of Sentora. “It’s an economic layer that prices risk, absorbs losses and continuously signals what’s actually safe.”

Institutional Integration and Security Firelight leverages Flare’s FAssets system to bring XRP into DeFi. Users deposit XRP, mint FXRP and stake it to receive stXRP — a liquid staking token that accrues rewards while remaining usable across the Flare ecosystem. Under phase 1, which is now live, Firelight offers audited vaults and liquid staking with no slashing risk. In phase 2, expected in the second quarter of 2026, Firelight will activate its full cover mechanism, allowing protocols across chains to purchase protection backed by the staked pool.

Large-scale deposits suggest institutional players are moving from observation to allocation. In a recent community discussion, Firelight’s Connor Sullivan cited Kraken and Coinbase as early adopters of DeFi integration, noting that many institutions are waiting for credible protection layers before committing capital at scale.

Sentora, which raised $25 million in Series A funding with support from Ripple, Flare and New Form Capital, specializes in institutional DeFi strategies. Its Smart Yields platform powers Kraken’s DeFi Earn product and serves institutional clients seeking compliant yield exposure. Firelight represents the culmination of four years of risk engineering, now deployed as a dedicated onchain underwriting engine. The protocol has completed audits by Openzeppelin and Coinspect and runs an active bug bounty program through Immunefi.

FAQ ❓ What is Firelight? Firelight is the first XRP staking and DeFi cover platform built on the Flare Network. How much XRP is staked? Firelight has surpassed 50 million XRP staked, with whale deposits over 1 million XRP each. Why does this matter for DeFi? The milestone highlights growing demand for risk protection after $137 million in DeFi exploits in Q1 2026. What comes next for Firelight? Phase 2 launches in Q2 2026, enabling full cross‑chain DeFi cover backed by staked FXRP.

Oil fell in early trade after President Trump said he's pausing attacks on Iran's energy sector for another 10 days as per Iran's request.

From the investor meetings to how shares are doled out, Elon Musk is navigating his own path.

The current conflict in the Middle East and the resulting closure of the Strait of Hormuz is, to put it mildly, a huge problem.

About 20% of all global oil supplies pass through the strait, and other options to move the oil and gas produced in the Persian Gulf are limited. The closure also affects some of the world's largest economies.

Japan imports 57% of its oil and gas through the Strait of Hormuz. South Korea imports 55%, India 50%, Taiwan 40%, and China 35%.

Now, all of those countries had been investing in their nuclear power capacity before the current conflict broke out.

Since 2015, Japan has been steadily reactivating its nuclear reactor fleet and reducing its dependence on oil and gas.

South Korea has plans for two new nuclear reactors, which will be brought online by 2038.

India has eight reactors under construction right now and China had a staggering 33 being built as of mid-2025.

But I think the throttling of the Strait of Hormuz has made a very good case for achieving a higher degree of energy independence.

After all, if it can be avoided, why would any government want the source of such a vital resource at the mercy of geopolitical tensions thousands of miles away?

That's precisely where Cameco (CCJ 3.99%) comes in.

Image source: Getty Images.

The fuel of the future All those reactors will need one resource to run: uranium.

And Canada's Cameco is the world's second-largest uranium miner. It was responsible for 15% of all the world's uranium produced in 2025.

The company owns some of the highest-grade uranium mines in the world in McArthur River/Key Lake and Cigar Lake. They are the world's largest high-grade uranium mine and one of the world's highest-grade uranium mines, respectively.

Uranium from those mines will be going to fuel India's reactors. In early March, Cameco signed a 22 million-pound uranium supply agreement with India that will see the country supplied by Cameco from 2027 to 2035.

And the company profits from China's nuclear build-out through its 49% stake in Westinghouse, an engineering company that produces the AP1000, the most advanced commercially available nuclear reactor in the world.

Today's Change

(

-3.99

%) $

-4.35

Current Price

$

104.67

China currently has four AP1000 reactors in operation and 14 of its 33 reactors under construction are AP1000s. The United States has two AP1000s in operation, with 10 planned, and India has selected six AP1000s for the next stage of its nuclear build-out.

Between its uranium production and the advanced reactors it can profit from through Westinghouse (to make no mention of its fuel production operations), Cameco is well suited to profit, not only from the U.S. Department of Energy's goal to triple America's nuclear capacity by 2050, but from Asia's nuclear renaissance as well.

The company's latest results make the case very clearly as well.

For 2025, its revenue climbed 10% over 2024 to $3.48 billion, and its adjusted net earnings per share (EPS) shot up 114%.

The current conflict in the Middle East has laid bare the fragility of modern energy markets, and it's no surprise countries around the world are looking to find a more stable power source.

Cameco is one of the best ways to play that trend, in 2026 and beyond.

The iShares Core MSCI Emerging Markets ETF (IEMG 3.33%) and the iShares MSCI Emerging Markets ETF (EEM 3.40%) both target emerging market equities, but IEMG covers a broader set of stocks at a far lower fee while EEM delivers similar performance with a narrower large- and mid-cap focus.

Both IEMG and EEM aim to give investors exposure to emerging markets, but IEMG includes small-cap stocks and charges less than one-seventh the fee. This comparison highlights key differences in cost, portfolio breadth, risk, and recent returns to help investors decide which may better suit their needs.

Snapshot (cost & size)MetricIEMGEEMIssuerISharesISharesExpense ratio0.09%0.72%1-yr return (as of Mar. 24, 2026)25.5%26.2%Dividend yield2.6%2.1%AUM$135.8 billion$25.2 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months.

IEMG is notably more affordable with a 0.09% expense ratio compared to EEM’s 0.72%, and it also offers a higher dividend yield, paying out 2.6% versus EEM’s 2.1%.

Performance & risk comparisonMetricIEMGEEMMax drawdown (5 y)(35.94%)(37.82%)Growth of $1,000 over 5 years$1,106$1,089What's insideEEM focuses on large- and mid-cap emerging market stocks, with 1,223 holdings as of its 23rd year. Technology is the largest sector at 34%, followed by financial services (19%) and consumer cyclicals (9%). Top holdings include Taiwan Semiconductor Manufacturing (TSM 6.29%), Samsung Electronics Ltd (SSU 7.55%), and Tencent Holdings Ltd (TCEHY 2.52%), and there are no notable quirks or overlays.

IEMG extends exposure to small-cap companies, holding 2,725 stocks in total. Its sector mix is nearly identical—technology (32%), financial services (19%), and consumer cyclicals (10%)—with the same leading positions in Taiwan Semiconductor Manufacturing, Samsung Electronics Ltd, and Tencent Holdings Ltd. The key difference is IEMG’s broader reach and inclusion of smaller companies, which may appeal to those seeking more comprehensive market coverage.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsFor investors seeking exposure to emerging markets stocks, iShares Core MSCI Emerging Markets ETF (IEMG) and the iShares MSCI Emerging Markets ETF (EEM) are both emerging market exchange-traded funds (ETFs) worthy of consideration. Here’s how they matchup with each other.

IEMG’s biggest edge is its expense ratio. IEMG has an expense ratio of only 0.09%, while its rival’s expense ratio is 0.72%. That means those who invest $10,000 in IEMG will pay $9 in fees per year, while those who invest $10,000 in EEM will pay $72 per year. What’s more, IEMG also boasts a higher dividend yield of 2.6%, while EEM has a dividend yield of 2.1%.

For EEM, recent performance is its main edge. EEM has generated a one-year return of 26.2%, while its rival has generated 25.6%.

In summary, most investors will favor IEMG, due to the lower fees and greater dividend yield. However, some investors may be swayed by EEM’s better recent performance.

A worker operates valves at the Rumaila oil field, as the country cuts nearly 1.5 million barrels per day of output amid halted exports following the closure of the Strait of Hormuz, in Basra,... Purchase Licensing Rights, opens new tab Read more

PERTH, March 27 (Reuters) - Oil prices fell in early trade on Friday and were down over a volatile week after U.S. President Donald Trump said talks with Iran to end the war were going "very well" ​and announced he would pause attacks on the country's energy plants for 10 days.

Brent ‌futures fell 90 cents, or 0.8%, to $107.11 per barrel as of 0024 GMT, while U.S. West Texas Intermediate futures lost 83 cents, or 0.88%, to $93.65 per barrel, trimming gains from a bullish previous session.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

On Thursday, Brent rose 5.7% while ​WTI gained 4.6% on fears of further escalation of the war, although trading volume for ​the front-month Brent contract was the lowest since February 27, the day before ⁠the United States and Israel began strikes on Iran.

However, Brent is headed for its first weekly fall ​in six weeks while WTI has fallen for a second consecutive week, with Trump talking up the prospect ​of ending the war.

"As per Iranian Government request ... I am pausing the period of Energy Plant destruction by 10 Days to Monday, April 6, 2026, at 8 P.M., Eastern Time," Trump said in a post on Truth Social on ​Thursday.

An Iranian official told Reuters that a 15-point U.S. proposal, conveyed to Tehran by Pakistan, was ​reviewed in detail on Wednesday by senior Iranian officials and the representative of Iran's supreme leader. The official called ‌the plan "one-side ⁠and unfair".

The U.S. president said on Thursday that Iran was letting 10 oil tankers transit the Strait of Hormuz as a goodwill gesture in negotiations. He said they were Pakistan-flagged vessels.

However, the U.S. has also sent thousands of troops to the Middle East, with Trump weighing whether to use ground forces to ​seize Iran's strategic oil ​hub of Kharg Island.

The war ⁠has nearly halted shipments through the Strait of Hormuz, which typically carries about a fifth of the world's crude oil and LNG supply, with International ​Energy Agency chief Fatih Birol describing the crisis as worse than the two oil ​shocks of ⁠the 1970s, as well as the impact of the Russia-Ukraine war on gas, put together.

The war on Iran has taken 11 million barrels of oil per day from global supply.

“For today, the markets are not assuming ⁠a ​huge impact, particularly in oil. If you look at the ​forward curve, they're assuming this will end quite fast and things will stabilise quite quickly,” Macquarie chief executive Shemara Wikramanayake told the ​Asia Pacific Financial and Innovation Symposium in Melbourne on Thursday.

Reporting by Helen Clark; Editing by Sonali Paul

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Edmonton, Alberta--(Newsfile Corp. - March 26, 2026) - Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) ("Canamera" or the "Company") is pleased to announce, further to its news releases dated February 27, 2026 and March 12, 2026, that the Company has closed its non-brokered private placement under the LIFE Exemption (as defined below) of 3,844,409 units of the Company (each a "Unit"), issued at a price of $0.55 per Unit, for aggregate gross proceeds of $2,114,424.95 (the "LIFE Offering").

Each Unit consists of one (1) common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to acquire one (1) Common Share at a price of $0.65 for a period of 24 months from March 26, 2026 (the "Closing Date").

The LIFE Units were issued pursuant to the Listed Issuer Financing Exemption (the "LIFE Exemption") under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by the Canadian Securities Administrator's Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. Accordingly, the Units will not be subject to a hold period in accordance with applicable Canadian securities laws.

In connection with the LIFE Offering, the Company paid $50,688.00 in cash finder's fees and issued 92,160 finder's warrants (the "Finders Warrants"). Each Finders Warrant entitles the holder to acquire one (1) Common Share at a price of $0.65 for a period of 24 months from the Closing Date. The Finders Warrants are subject to a statutory hold period of four months and one day.

The Company intends to use the net proceeds from the LIFE Offering to advance its projects, maintain existing property acquisition obligations, for working capital and general corporate purposes, including investor relations and as more specifically described in the LIFE Offering Document filed on SEDAR+.

Concurrent Non-Brokered Private Placement

The Company also wishes to announce the closing of its previously announced concurrent non-brokered private placement of 3,787,155 flow-through units ("FT Units"), at a price of $0.66 per FT Unit, for aggregate gross proceeds of $2,499,522.30 (the "Concurrent Offering").

Each FT Unit consists of one (1) flow through Common Share and one-half of one Common Share purchase warrant (each whole warrant, a "FT Warrant"). Each FT Warrant will entitle the holder to acquire one (1) Common Share at a price of $0.75 for a period of 24 months from the Closing Date.

In connection with the Concurrent Offering, the Company paid $60,000.14 in cash finder's fees and issued 90,909 finder's warrants (the "FT Finders Warrants"). Each FT Finders Warrant entitles the holder to acquire one (1) Common Share at a price of $0.75 for a period of 24 months from the Closing Date.

The Company intends to use the proceeds of the Concurrent Offering to incur "Canadian exploration expenses" (CEE), such that they qualify as flow-through mining expenditures for purposes of the Income Tax Act (Canada) and can be renounced to the purchasers thereof.

All securities issued in connection with the Concurrent Offering are subject to a statutory hold period of four months and one day.

The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Canamera Energy Metals Corp.

Canamera Energy Metals Corp. is a rare earth elements exploration and development company with an expanding project portfolio across Brazil, the United States, and Canada. The Company is focused on advancing ionic clay REE projects in Brazil and critical mineral assets in North America to support Western rare earth supply chain independence. For more information, visit www.canamerametals.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements are typically identified by words such as: "believe", "expect", "anticipate", "intend", "estimate", "plans", "strategy", "opportunity", "positions" and similar expressions, or are those which, by their nature, refer to future events. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements in this release include, but are not limited to, statements regarding the Concurrent Offering and LIFE Offering as contemplated, the receipt of CSE approval in respect of the Concurrent Offering and LIFE Offering, and the Company's intended use of proceeds therefrom, as well as the Company's ability to advance its projects or to acquire new mineral properties.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including: the use of proceeds therefrom being different than what is currently intended; the Company's inability to identify suitable staking targets; completion of satisfactory due diligence on potential projects; successful negotiation of acquisition terms; availability of financing; changes in commodity prices and market conditions for rare earth elements; regulatory or permitting delays; geopolitical developments affecting rare earth supply chains; and competition for rare earth properties in the United States. Additional risk factors can be found in the Company's public disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise such statements, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290185

Source: Canamera Energy Metals Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Tokenwell Platforms Inc. (CSE: TWEL) (OTCQB: TWELF) (FSE: Y920) ("Tokenwell" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of unsecured convertible debentures (the "Debentures"). The Company expects to raise aggregate gross proceeds of up to $600,000 under the Offering.

The Debentures will bear interest at a rate of 10.0% per annum, calculated monthly and accrued, and payable in common shares of the Company (each a "Share") upon conversion or at maturity at the Conversion Price (as defined below). The Debentures will mature on the date that is 12 months following the date of issuance (the "Maturity Date").

The outstanding principal together with accrued interest may be converted into Shares at a price of $0.06 per Share (the "Conversion Price") at any time on or before the Maturity Date. On the Maturity Date, the holders of the Debentures may convert the outstanding principal amount, together with any accrued interest thereon, into Shares at the Conversion Price.

The Company intends to use the net proceeds from the Offering for general working capital purposes.

The Offering is expected to close on or before April 15, 2026, or such other date as the Company may determine, and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals.

In connection with the closing of the Offering, the Company may pay finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Completion of the Offering remains subject to regulatory approval. All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

On Behalf of the Company

~Timothy Burgess~

Timothy J. Burgess

CEO and Director

About Tokenwell Platforms Inc. (CSE: TWEL) (OTCQB: TWELF) (FSE: Y920)

Tokenwell is a publicly listed cutting-edge cryptocurrency platform dedicated to making digital assets accessible, secure, and efficient for users worldwide. With a focus on innovation and user-centric design, Tokenwell empowers individuals and businesses to engage with the crypto economy confidently. For more information about Tokenwell, its upcoming launches, product benefits and features, Crypto users should visit www.tokenwell.io and download the Tokenwell app on iOS or Android. Potential investors are invited to visit www.tokenwell.com and everyone should follow us on LinkedIn, X & Telegram, and also subscribe to our News Alert opportunity for free and timely notifications from the Company.

Tokenwell Disclaimer – Tokenwell Platforms Inc. is not an investment adviser or commodity trading advisor. Tokenwell makes no representation regarding the advisability of investments linked to its products. Assets remain on users' own exchanges. Terms and conditions available at tokenwell.com.

Forward-Looking Statements – This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the expected closing date of the Offering; the anticipated proceeds to be raised under the Offering; the intended use of any proceeds raised under the Offering; and the payment of any finder's fees in connection with the Offering. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited, our ability to continue with our development efforts, our efforts to grow our business and operations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and the Company undertakes no duty to update these forward-looking statements.

Neither the CSE nor its Regulatory Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290188

Source: Tokenwell Platforms Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Terna S.p.A. (TEZNY) Q4 2025 Earnings Call March 26, 2026 12:00 PM EDT

Company Participants

Stefano Gamberini - Head of Investor Relations
Giuseppina Di Foggia - CEO, GM & Non-Independent Director
Francesco Beccali - Chief Financial Officer

Presentation

Operator

Good afternoon, ladies and gentlemen, and welcome to Terna's Full Year 2025 Consolidated Results Presentation. [Operator Instructions] Please be advised that today's conference is being recorded. I would like to hand the conference over to our host speaker today, Mr. Stefano Gamberini, Head of Investor Relations. Please go ahead, sir.

Stefano Gamberini
Head of Investor Relations

Thank you, and good afternoon, everyone, and welcome to Terna's Full Year 2025 Results Presentation. The call will be hosted by our CEO and General Manager, Giuseppina Di Foggia; and our CFO, Francesco Beccali. Following the presentation, we will have the Q&A session. So we kindly ask you to send any questions you might have to our e-mail address, [email protected]. Please Giuse.

Giuseppina Di Foggia
CEO, GM & Non-Independent Director

Thank you, Stefano. Good afternoon, everyone. Let me start by giving you an overview of the key highlights of 2025. This year confirms we are on track with the execution of our plan while accelerating investments in maintaining financial strength.

In March 2025, we updated our 2024-2028 industrial plan. Total investment now stands at EUR 17.7 billion, 7% higher compared with the previous version of our plan and with a consistent plus 77% versus the 2022 plan. Out of this amount, EUR 16.6 billion are allocated to regulated investments.

As of today, this is Terna's largest investment program. At the beginning of last year, we also presented our national development plan. It foresees more than EUR 23 billion of investments between 2025 and 2034. Once projects in this plan are completed, the transmission capacity between Southern and Northern Italy will increase from

1.01K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On March 25, 2026, Anavex issued a press release "announc[ing] that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA)." The press release said that "[t]he decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time." 

On this news, Anavex's stock price fell $1.45 per share, or 34.61%, to close at $2.74 per share on March 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of On Holding AG ("On" or the "Company") (NSYE: ONON). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether On and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On March 25, 2026, On announced that Martin Hoffmann will step down as Chief Executive Officer in May as part of a "planned hiatus" to pursue philanthropic interests, with co-founders David Allemann and Caspar Coppetti to serve as co-CEOs following Hoffmann's departure. The announcement followed the departure of previous CEO Marc Maurer just one year earlier. 

Following this news, On's stock price fell $4.43 per share, or 11.19%, to close at $36.16 per share on March 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

The Warehouse Group Limited (WHGPF) Q2 2026 Earnings Call March 26, 2026 4:15 PM EDT

Company Participants

John William Journee
Mark Stirton - Chief Executive Officer
Stefan Knight - Chief Financial Officer

Conference Call Participants

Kieran Carling - Craigs Investment Partners Limited, Research Division
Guy Edward Hooper - Jarden Limited, Research Division
Paul Koraua - Forsyth Barr Group Ltd., Research Division

Presentation

Operator

Thank you for standing by, and welcome to The Warehouse Group Limited Fiscal Year 2026 Interim Results. [Operator Instructions]

I would now like to hand the conference over to Mr. John Journee, Group Chief Executive Officer. Please go ahead.

John William Journee

[Foreign Language] and good morning, everyone. Welcome to the Warehouse Group's FY '26 interim results presentation. Thank you for joining us today. I'm John Journee. It's a privilege to be speaking with you as the first time as Chair of The Warehouse Group. Joining me today are Mark Stirton, our Group Chief Executive Officer; and Stefan Knight, our Group Chief Financial Officer. I will start with an update of our first half and then hand to Mark to step through the group's performance and progress. Stef will then take you through the financial detail, and Mark will return at the end of the talk to talk about the second half of the year. As always, there will be an opportunity to ask questions at the end of the presentation.

From the Board's perspective, the group is on the right path, and we are seeing execution and proof. This progress has been delivered in an extremely challenging retail environment with volatile macroeconomic conditions. In these circumstances, the group delivered a solid result for the first half, holding sales, reducing costs and improving profitability.

Sales were $1.6 billion, up 0.3% on the prior year half. Gross profit was $520.5 million, down slightly on the

10.11K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BCPC over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Chainlink (LINK) is showing early signs of stabilization, but the broader market structure remains firmly bearish — and that contradiction defines where the asset stands today. For several months, LINK has been locked in a sustained downtrend, consistently trading below its key moving averages while failing to hold any meaningful price recovery. The 50, 100, and 200 exponential moving averages (EMAs) all continue to slope downward, with price action remaining compressed beneath all three. This alignment keeps LINK in a bearish regime, where any upside movement is treated as a corrective bounce rather than the start of a new bullish impulse.

That said, recent behavior is worth noting. Instead of continuing to post lower lows, LINK has started carving out a horizontal base in the $8–$9 price range. Selling pressure has visibly eased, and volatility has contracted — both signs that aggressive downside momentum may be losing steam. The market is no longer in active distribution mode, even if it has not yet shifted into accumulation.

From a technical standpoint, a push toward the $10 level is plausible, but it hinges entirely on reclaiming short-term resistance. The most immediate hurdle is the 50 EMA, which sits just above current price levels. Should LINK manage to break above it with conviction and sustain that level, the $10 zone becomes the next logical target — an area reinforced by both prior consolidation history and psychological price resistance.

Until that breakout materializes, the path of least resistance remains to the downside. Traders should watch for a confirmed close above the 50 EMA as the first real signal that sentiment is beginning to shift. Without it, any rally continues to carry the risk of being faded back into the range.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>